RudaCure Inc., which develops treatments for intractable diseases, was announced as a final selection for the 中小企业部' 初创企业 Leap Forward Package Program on April 28th.
This program funding is expected to be utilized for research on commercializing the peptide drug for 疼痛治疗药 currently under development, as well as for external promotion activities.
This is expected to serve as the starting point for RudaCure Inc., which is entering its fifth year since founding, to take a leap forward.
Starting with this program, RudaCure has completed all preparations for 临床试验 of the 干眼症治疗药 and 眼部 mucosal damage treatment currently under development, and will begin full-scale reagent production for 临床试验 starting next month.
Additionally, a busy schedule of commercialization activities is planned, including BIO KOREA in May, the presentation of RCI002 临床前结果 for 化疗引起的疼痛 treatment at ASCO in June, and attendance at BIO USA.
At BIO KOREA, meetings are scheduled with companies showing potential as multinational partners for RCI002,
and at BIO USA, collaboration with multinational partners interested in 兽用 药物开发 is also anticipated, offering a chance to witness the company's rapid growth.
